A 4852: Revises certain requirements for prescription of Schedule II controlled dangerous substances via telemedicine and telehealth without in-person examination or review.*
A 4852 status: Introduced — Approved P.L.2026, c.40 (updated Jul 8, 2026).
What this bill does
Overall score
Bill summary
OfficialThis bill changes the rules for how doctors can prescribe strong, potentially addictive medications during a video call without ever meeting you in person. Lawmakers are currently deciding whether to pass these new requirements.
Key analysis
Impact analysis
Environment
Benefits
- No direct sector effect identified.
Risks
- No direct sector effect identified.
Economy
Benefits
- Increases market efficiency for telehealth providers.
- Reduces travel costs for patients in remote areas.
Risks
- Imposes administrative burden on providers to ensure compliance.
- Potentially increases costs for monitoring and regulatory oversight.
Society
Benefits
- Expands access for patients with chronic conditions.
- Allows flexibility for vulnerable populations like hospice patients.
Risks
- Potential for misuse of addictive Schedule II substances.
- Clinical limitations of remote assessment for complex psychiatric stimulant management.
How trustworthy & consequential it is
Source
LegiScan
Confidence
highhigh
Analysis status
LegiScan full bill text
Relaxing in-person examination requirements for Schedule II substances carries inherent risks of diversion and misuse.
Analysis relies exclusively on the provided text of A 4852.
Where it stands
Introduced
CurrentApproved P.L.2026, c.40.
Committee
UpcomingFloor
UpcomingGovernor
UpcomingEnacted
UpcomingHow it affects your district
Set your location
Add your district to see how this bill may affect your community and who to contact.
Take action
Contact your representatives
Let them know how you feel about this bill.
Share your view
Join the discussion and see what others are saying.
Track this bill
Stay updated on progress and changes.